MOZOBIL

Details for Australian Trade Mark No. 1033173 (hide)

Owner Anormed Inc.

Convention CA 9 JUNE 2004 1,219,832

Service Phillips Ormonde Fitzpatrick

Various Convention priority claimed: dated 9 June 2004, Canada, No. 1,219,832, in respect of PHARMACEUTICAL AND MEDICINAL PREPARATIONS FOR THE TREATMENT OF HIV, INFLAMMATION, ARTHRITIS, ASTHMA, CANCER, CELL TRANSPLANTS AND CELL TRANSPLANT REJECTION, ORGAN TRANSPL

Filing Date 6 December 2004

Classes

Class 5 Pharmaceutical, medicinal and veterinary preparations, including pharmaceutical and medicinal preparations for the treatment of HIV, inflammation, arthritis, asthma, cancer, cell transplants and cell transplant rejection, organ transplants and organ transplant rejection, angiogenesis, multiple sclerosis, bacterial infection, peripheral blood stem cell mobilization, cardiovascular diseases, lymphoma, tissue regeneration, tissue repair, leukemia, drug-induced anemia, retrovirus, hematopoietic deficit resulting from chemotherapy or radiation therapy, elevation of white blood cells, and ophthalmic diseases, including age related macular generation and diabetic retinopathy

Event Publications

6 January 2005 Application Accepted

5 May 2005 Trade Mark Registered/Protected

17 January 2008 Subsequent Owners/Holder Registered - Full Assignment

  Anormed Inc. is the full asignee of Genzyme Corporation.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the ATMOSS Australian Trade Mark On-line Search System.

Next and Previous Trademarks/Applications

1033174

1033172